Chimeric Therapeutics (ASX:CHM) Net Cash per Share : A$-0.01 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Chimeric Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 was A$-0.01.

The historical rank and industry rank for Chimeric Therapeutics's Net Cash per Share or its related term are showing as below:

During the past 3 years, the highest Price-to-Net-Cash Ratio of Chimeric Therapeutics was 25.06. The lowest was 4.60. And the median was 9.32.

ASX:CHM's Price-to-Net-Cash is not ranked ^*
in the Biotechnology industry.
Industry Median: 4.01
* Ranked among companies with meaningful Price-to-Net-Cash only.

Chimeric Therapeutics Net Cash per Share Historical Data

The historical data trend for Chimeric Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Net Cash per Share Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Net Cash per Share

0.03

0.02

-0.03

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Cash per Share	Get a 7-Day Free Trial			0.01	0.02	-0.01	-0.03	-0.01

Competitive Comparison of Chimeric Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Chimeric Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Price-to-Net-Cash falls into.

Chimeric Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Chimeric Therapeutics's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

	Net Cash per Share (A: Jun. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.363	-	16.715	-	0)	/	506.686
=	-0.03

Chimeric Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.525	-	12.825	-	0)	/	725.841
=	-0.01

Chimeric Therapeutics (ASX:CHM) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Chimeric Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines